Cargando…

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

BACKGROUND: Nilotinib (Tasigna®) is a second-generation tyrosine kinase inhibitor that shows faster and deeper molecular responses (MR) in comparison to Imatinib as initial therapy in chronic phase chronic myeloid leukemia (CML). Efficacy and safety data for nilotinib in the Asian population is scar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaidi, Uzma, Kaleem, Bushra, Borhany, Munira, Maqsood, Sidra, Fatima, Naveena, Sufaida, Gul, Ansari, Saqib Hussain, Farzana, Tasneem, Shamsi, Tahir Sultan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388993/ https://www.ncbi.nlm.nih.gov/pubmed/30863159 http://dx.doi.org/10.2147/CMAR.S181911

Ejemplares similares

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients
por: Zaidi, Uzma, et al.
Publicado: (2020)

Peripheral Blood Stem Cell Harvest HPC Count Is an Effective Surrogate Marker for CD34+ Cell Count in Allogeneic Stem Cell Transplant Setting
por: Jamal, Aisha, et al.
Publicado: (2020)

Thrombocytopenia in Pregnancy: Identification and Management at a Reference Center in Pakistan
por: Borhany, Munira, et al.
Publicado: (2022)

Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan
por: Mukry, Samina Naz, et al.
Publicado: (2022)

Prevalence of transfusion transmissible infections in blood donors of Pakistan
por: Arshad, Aisha, et al.
Publicado: (2016)

Bleeding disorders in the tribe: result of consanguineous in breeding
por: Borhany, Munira, et al.
Publicado: (2010)

Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review
por: Zaidi, Uzma, et al.
Publicado: (2017)

Chromosomal Breakage in Fanconi Anemia and Consanguineous Marriages: A Social Dilemma for Developing Countries
por: Siddiqui, Fakeha, et al.
Publicado: (2020)

The Sokal Hoax: the sham that shook the Academy
por: Lingua Franca. USA
Publicado: (2000)

The Impact of ABO Incompatibility on the Outcomes of Hematopoietic Stem Cell Transplantation: A Single-Center Study From Pakistan
por: Borhany, Munira, et al.
Publicado: (2023)

Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan
por: Zaidi, Uzma, et al.
Publicado: (2022)

Cophenetic metrics for phylogenetic trees, after Sokal and Rohlf
por: Cardona, Gabriel, et al.
Publicado: (2013)

Laboratory Diagnosis of Malaria: Comparison of Manual and Automated Diagnostic Tests
por: Mukry, Samina Naz, et al.
Publicado: (2017)

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups
por: Zehra, Samreen, et al.
Publicado: (2016)

Blood Ordering and Transfusion Practices: An Insight Toward Better Utility of Blood Products
por: Waheed, Samra, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan
por: Younas, Amber, et al.
Publicado: (2020)

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
por: Pfirrmann, Markus, et al.
Publicado: (2020)

The Frequency of Rh Phenotype and Its Probable Genotype
por: Tariq, Faryal, et al.
Publicado: (2022)

Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country
por: Thakur, Warkha, et al.
Publicado: (2022)

Molecular epidemiology of β-thalassemia in Pakistan: Far reaching implications
por: Ansari, Saqib H., et al.
Publicado: (2012)

Emerging Anti-Microbial Resistance in Febrile Neutropenia: Is it high time to evaluate quality control measures?
por: Mahar, Uzma, et al.
Publicado: (2020)

Reticulated Platelet Count as a Diagnostic Tool in Immune Thrombocytopenia (ITP)
por: Butt, Aqsa Javed, et al.
Publicado: (2023)

Correlation Between Serum Ferritin and Degree of Hepatic Fibrosis on Fibroscan in Thalassemic Patients
por: Ali, Muhammad Shujat, et al.
Publicado: (2023)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

PB2031: NEXT GENERATION SEQUENCING IN MYELOID NEOPLASMS: DEVELOPING WORLD DATA FROM SINGLE CENTRE
por: Anwar, Nida, et al.
Publicado: (2023)

The Outcome of Hodgkin Lymphoma With Reference to Prognostic Markers
por: Ahmed, Rehana, et al.
Publicado: (2022)

Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
por: Xia, Leiming, et al.
Publicado: (2015)

Assessment of Hepatic Profile in Acquired Aplastic Anemia: An Experience From Pakistan
por: Thakur, Warkha, et al.
Publicado: (2022)

Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India
por: Kuntegowdanahalli, Lakshmaiah Chinnagiriyappa, et al.
Publicado: (2016)

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
por: Zhang, Xiao-Shuai, et al.
Publicado: (2021)

Homozygous CALR Mutation in Primary Myelofibrosis and Its Effect on Disease Phenotype: A Case Report and Review of the Literature
por: Rizvi, Qurratulain, et al.
Publicado: (2019)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment
por: Munawar Ali, Rabeea, et al.
Publicado: (2023)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Clinical and Microbiological Profile of Pathogens in Febrile Neutropenia in Hematological Malignancies: A Single Center Prospective Analysis
por: Taj, M., et al.
Publicado: (2015)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e7t6ehbkh8f3eksdqeg2osd1v8